Document Detail

Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.
MedLine Citation:
PMID:  16101143     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The B7-H1/PD-1 pathway has been demonstrated to be involved in tumor evasion. In a previous study, we constructed a eukaryotic expression plasmid (pPD-1A), which expresses soluble PD-1 (sPD-1). In this study, the question of whether or not the blockade of B7-H1 with sPD-1 in vivo and vitro can improve antitumor immunity was investigated. MATERIALS AND METHODS: The proliferation of lymphocytes activated by dendritic cells (DCs), which were treated with sPD-1 in vitro, was detected with MTT colorimetry. Mice inoculated with H22 cells were treated by intramuscular injection with pPD-1A. The mRNA expression was analyzed with RT-PCR. RESULTS: The early activation of lymphocytes in vitro was partly improved by sPD-1 blockade. The growth of H22 cells was inhibited significantly after pPD-1A administration. The mRNA expression of 4-1BB, B7.1, IFN-gamma and TNF-alpha of lymphocytes was up-regulated and that of OX40 and IL-10 was down-regulated after pPD-1A administration. CONCLUSION: Blockade of the PD-1/B7-H1 pathway with sPD-1 may be a promising strategy for immunotherapy for hepatocarcinoma. Both cytokines and co-stimulatory molecules of lymphocytes could be regulated by sPD-1 blockade.
Lanxiang He; Guimei Zhang; Yufei He; Hangang Zhu; Hui Zhang; Zuohua Feng
Related Documents :
20377993 - Increased tumor-specific cd8+ t cell induction by dendritic cells matured with a clinic...
543373 - Phagocytosis-stimulating mediators in insects.
18607783 - The therapeutic potential of embryonic and adult stem cells for skeletal muscle regener...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  25     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2005 Sep-Oct
Date Detail:
Created Date:  2005-08-16     Completed Date:  2005-10-13     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  3309-13     Citation Subset:  IM    
Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / biosynthesis,  genetics,  immunology
Antigens, CD137
Antigens, CD80 / biosynthesis,  genetics,  immunology
Antigens, Differentiation / biosynthesis,  genetics,  immunology
Antigens, Surface / genetics,  immunology*
Apoptosis Regulatory Proteins
Cell Line, Tumor
Dendritic Cells / immunology
Interferon-gamma / biosynthesis,  genetics,  immunology
Interleukin-10 / biosynthesis,  genetics,  immunology
Liver Neoplasms, Experimental / genetics,  immunology*
Lymphocyte Activation
Membrane Glycoproteins / antagonists & inhibitors*,  biosynthesis,  genetics,  immunology
Mice, Inbred BALB C
Peptides / antagonists & inhibitors*,  genetics,  immunology
Plasmids / genetics
RNA, Messenger / biosynthesis,  genetics
Receptors, Nerve Growth Factor / biosynthesis,  genetics,  immunology
Receptors, Tumor Necrosis Factor / biosynthesis,  genetics,  immunology
Tumor Necrosis Factor-alpha / biosynthesis,  genetics,  immunology
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, CD137; 0/Antigens, CD80; 0/Antigens, Differentiation; 0/Antigens, Surface; 0/Apoptosis Regulatory Proteins; 0/Membrane Glycoproteins; 0/OX40Ig; 0/Pdcd1 protein, mouse; 0/Pdcd1lg1 protein, mouse; 0/Peptides; 0/RNA, Messenger; 0/Receptors, Nerve Growth Factor; 0/Receptors, Tumor Necrosis Factor; 0/Tnfrsf9 protein, mouse; 0/Tumor Necrosis Factor-alpha; 130068-27-8/Interleukin-10; 82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung.
Next Document:  Sensitisation of Ehrlich ascitic tumour cells to methotrexate by inhibiting glutaminase.